Aptevo Therapeutics, Inc. (APVO)

Aptevo Therapeutics' stock experienced volatility in the past six months. A reverse stock split was executed to maintain Nasdaq compliance. Mipletamig delivered a 100% remission rate in Cohort 3 of the Phase 1b/2 RAINIER trial for AML. Aptevo announced an $8 million at-the-market equity offering with warrants. The company raised $15.9 million in Q2 2025, $18.7 million in Q3 2025, and completed a Follow-on Equity Offering of approximately $11.8 million. Aptevo expanded its CD3 bispecific portfolio by introducing APVO455 and two trispecific T-cell engagers, APVO451 and APVO452. The share price declined by 87.47% from November 26, 2024, to November 25, 2025.

There is no information available to indicate demand seasonality for Aptevo Therapeutics, Inc.'s products and services. Demand for its products would primarily be driven by medical need, disease prevalence, and regulatory approvals, rather than seasonal patterns.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapeutic candidates for cancer treatment, utilizing its ADAPTIR™ and ADAPTIR-FLEX™ platforms to create antibody candidates. Its lead candidate, mipletamig, is in Phase 1b/2 trials for AML and MDS. Other candidates include ALG.APV-527 in Phase 1 trials for solid tumors, APVO455 targeting solid tumors, APVO451 and APVO452 as trispecific T-cell engagers, APVO442 for prostate cancer, APVO603 for solid tumors, and APVO711 for solid tumors.

Aptevo Therapeutics Inc. is headquartered in Seattle, Washington, USA, and focuses on developing cancer immunotherapies in the United States.

Aptevo Therapeutics' brand reputation has been influenced by clinical advancements and financial events. Positive impacts include the remission rate in the RAINIER trial and the expansion of its antibody pipeline. Negative impacts include the reverse stock split, multiple equity offerings, and a substantial decline in stock price. Limited market visibility also affects brand perception.

Aptevo Therapeutics Inc. has a mixed ownership structure. Institutional investors own approximately 2.93% to 8.06% of the stock. Fuad Elhibri is the largest individual shareholder, owning 17.93% of the company. Insiders own approximately 21.29% of the company's stock. Retail investors hold the largest portion of the stock, at approximately 75.78% to 98.90%.